+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antimalarial Drugs Market - Global Forecast 2025-2030- Product Image
Antimalarial Drugs Market - Global Forecast 2025-2030- Product Image
Sale

Antimalarial Drugs Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967662
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Antimalarial Drugs Market is evolving rapidly in response to shifting disease patterns, growing resistance, and the continual need for innovative therapeutic solutions. Strategic investment, policy shifts, and technological adoption continue to reshape competitive dynamics, compelling decision-makers to rethink approaches in procurement, supply chain management, and drug development.

Market Snapshot: Antimalarial Drugs Market Growth and Outlook

The Antimalarial Drugs Market grew from USD 1.76 billion in 2024 to USD 1.87 billion in 2025. It is expected to continue growing at a CAGR of 5.95%, reaching USD 2.50 billion by 2030. This progression reflects consistent demand from both public health programs and private sectors worldwide, with particular drivers including rising resistance rates, expanded prophylaxis initiatives, and ongoing innovation in drug delivery and formulation. Market expansion is also influenced by regulatory developments, changing procurement models, and the need to address emerging disease hotspots.

Scope & Segmentation of the Antimalarial Drugs Market

This comprehensive market research segments antimalarial drugs across key dimensions to provide actionable insight for stakeholders:

  • Drug Classes: Artemisinin-based combination therapies; non-artemisinin therapies including chloroquine, mefloquine, primaquine, and quinine.
  • Routes of Administration: Injectable and oral options, including solutions for rapid and community-based interventions.
  • Formulations: Injectables, suspensions, and tablets, addressing different patient needs and operational contexts.
  • Distribution Channels: Hospital, online, and retail pharmacies, supporting varied settings from acute care to remote outreach.
  • End Users: Ambulatory care centers, clinics, and hospitals, each shaping product uptake through unique clinical workflows.
  • Regional Segmentation: Americas (including the United States, Canada, and Latin America), Europe, Middle East & Africa, and Asia-Pacific, reflecting unique epidemiological and procurement landscapes.
  • Pharmaceutical Innovators: Major industry participants such as Novartis International AG, GlaxoSmithKline plc, Sanofi S.A., Cipla Limited, Viatris Inc., Pfizer Inc., Sun Pharmaceutical Industries Limited, Ipca Laboratories Limited, Dr. Reddy's Laboratories Limited, and Bayer Aktiengesellschaft.

Key Takeaways for Senior Decision-Makers

  • Combination therapy is the standard of care, helping minimize resistance and promote long-term disease management, with differentiated adoption across geographies.
  • Evolving formulations such as single-dose and pediatric-friendly presentations are closing critical gaps in treatment efficacy and adherence.
  • Strategic alliances, such as public-private partnerships and technology transfer initiatives, enhance manufacturing agility and supply resilience regionally.
  • Regional procurement approaches vary widely, shaped by local health system maturity, regulatory frameworks, and funding landscapes.
  • Integration of digital technology and real-world data supports post-market surveillance and accelerates regulatory approval cycles for innovative regimens.
  • Sustained investment in research, targeting new molecular entities and delivery systems, is crucial for addressing emerging resistance and ensuring future market growth.

Tariff Impact on the Global Supply Chain

Recent United States tariffs on pharmaceutical imports have disrupted global antimalarial supply chains. Companies face higher input costs and new logistical hurdles for sourcing APIs, excipients, and finished formulations from major manufacturing centers. Some stakeholders are diversifying suppliers, revisiting inventory and sourcing models, and coordinating with regional producers across Asia-Pacific and Africa to limit disruptions. Budgetary pressures have increased for public health agencies, prompting new approaches in procurement and financial planning.

Methodology & Data Sources

This analysis leverages comprehensive primary interviews with leaders from pharmaceutical, supply chain, and clinical communities, along with structured surveys from procurement authorities. Secondary sources—including peer-reviewed journals, patent registries, open statistical databases, and regulatory updates—were integrated using advanced segmentation and scenario-mapping techniques. Triangulation of data and expert validation ensures reliable, actionable findings.

Why This Report Matters for Your Antimalarial Strategy

  • Enables senior leaders to anticipate regulatory, trade, and supply chain shifts, allowing agile adaptation to new market realities.
  • Supports optimal product portfolio and procurement decisions with clarity on regional and operational drivers.
  • Facilitates partnerships and innovation by outlining competitive positioning and unmet needs across the therapeutic landscape.

Conclusion

The Antimalarial Drugs Market is at a pivotal point, shaped by evolving science, trade policies, and regional strategies. Stakeholders equipped with targeted, data-driven insights will be best positioned to achieve sustainable health outcomes and address future challenges in global malaria control.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increased adoption of single-dose tafenoquine for radical cure of Plasmodium vivax malaria in remote communities
5.2. Emergence of pediatric-friendly antimalarial granule formulations improving treatment adherence in sub-Saharan Africa
5.3. Growth of generic artemisinin combination therapies facing pricing pressure and regulatory variations across key Asian markets
5.4. Rising investments in next-generation triple combination antimalarial regimens to combat multi-drug resistant strains in Southeast Asia
5.5. Integration of digital adherence technologies and mobile health platforms to monitor antimalarial treatment outcomes in rural zones
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antimalarial Drugs Market, by Drug Class
8.1. Introduction
8.2. Artemisinin Based Combination Therapy
8.2.1. Artemether Lumefantrine
8.2.2. Artesunate Amodiaquine
8.2.3. Artesunate Mefloquine
8.2.4. Dihydroartemisinin Piperaquine
8.3. Non Artemisinin Therapies
8.3.1. Chloroquine
8.3.2. Mefloquine
8.3.3. Primaquine
8.3.4. Quinine
9. Antimalarial Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.3. Oral
10. Antimalarial Drugs Market, by Formulation
10.1. Introduction
10.2. Injectables
10.3. Suspensions
10.4. Tablets
11. Antimalarial Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Antimalarial Drugs Market, by End User
12.1. Introduction
12.2. Ambulatory Care Centers
12.3. Clinics
12.4. Hospitals
13. Americas Antimalarial Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Antimalarial Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Antimalarial Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis International AG
16.3.2. GlaxoSmithKline plc
16.3.3. Sanofi S.A.
16.3.4. Cipla Limited
16.3.5. Viatris Inc.
16.3.6. Pfizer Inc.
16.3.7. Sun Pharmaceutical Industries Limited
16.3.8. Ipca Laboratories Limited
16.3.9. Dr. Reddy's Laboratories Limited
16.3.10. Bayer Aktiengesellschaft
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANTIMALARIAL DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ANTIMALARIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ANTIMALARIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ANTIMALARIAL DRUGS MARKET: RESEARCHAI
FIGURE 26. ANTIMALARIAL DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. ANTIMALARIAL DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. ANTIMALARIAL DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTIMALARIAL DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 97. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 98. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 99. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 100. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 101. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 102. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 103. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 104. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 105. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 106. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 107. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 112. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 113. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 114. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 115. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 116. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 117. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 118. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 119. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 120. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 121. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 184. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 185. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 186. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 187. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 188. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 189. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 190. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 191. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 192. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 193. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 198. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 199. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 200. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 201. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 202. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 203. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 204. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 205. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 206. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 207. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 226. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 227. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 228. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 229. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 230. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 231. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 234. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 235. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 240. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 241. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 242. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 243. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 244. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 245. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 248. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 249. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 282. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 286. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 288. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 290. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 292. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 296. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 297. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 298. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 299. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 300. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 301. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 302. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 303. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 304. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 305. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 308. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 309. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 310. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 311. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 312. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 313. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
TABLE 314. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2030 (USD MILLION)
TABLE 315. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 316. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 317. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 318. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 319. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 320. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 321. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 322. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 323. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 324. QATAR ANTIMALARIAL DRU

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Antimalarial Drugs market report include:
  • Novartis International AG
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Cipla Limited
  • Viatris Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Ipca Laboratories Limited
  • Dr. Reddy's Laboratories Limited
  • Bayer Aktiengesellschaft

Table Information

Report AttributeDetails
No. of Pages199
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.87 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.5 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antimalarial Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Antimalarial Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Anti-Malarial Medicines - Global Strategic Business Report - Product Image

Anti-Malarial Medicines - Global Strategic Business Report

  • Report
  • 288 Pages
  • Global
From
India Antimalarial Drugs Market, By Region, Competition, Forecast & Opportunities, 2020-2030F - Product Image

India Antimalarial Drugs Market, By Region, Competition, Forecast & Opportunities, 2020-2030F

  • Report
  • 87 Pages
  • India
From
Antimalarial Agents. Design and Mechanism of Action - Product Image

Antimalarial Agents. Design and Mechanism of Action

  • Book
Pharmacokinetics and Pharmacodynamics of Antimalarial Drugs Used in Combination Therapy - Product Image

Pharmacokinetics and Pharmacodynamics of Antimalarial Drugs Used in Combination Therapy

  • Book
From

About the Antimalarial Market

The antimalarial market is a subset of the infectious diseases drugs market, which focuses on the treatment and prevention of malaria. Antimalarial drugs are used to treat and prevent the spread of the Plasmodium parasite, which is responsible for the disease. These drugs are typically administered orally, intravenously, or intramuscularly, depending on the severity of the infection. Common antimalarial drugs include chloroquine, artemisinin, and mefloquine. In addition to antimalarial drugs, the market also includes insecticides, insect repellents, and other preventive measures. These products are used to reduce the risk of infection by controlling the mosquito population, which is the primary vector for the Plasmodium parasite. Notable companies in the antimalarial market include GlaxoSmithKline, Sanofi, Novartis, and Merck. These companies produce a variety of antimalarial drugs, insecticides, and other preventive measures. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.